Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$363,678
in 3 filings, $327K under 10b5-1 plans

Net −$363,678. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-06-03 BAKER BROS. ADVISORS LP Director Grant or award +6,408 343,275
2026-06-03 BAKER BROS. ADVISORS LP Director Grant or award +6,408 3,422,366
2026-06-03 BAKER BROS. ADVISORS LP Director Grant or award · Non-Qualified Stock Option (right to buy) +19,226 19,226
2026-06-03 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +19,226 19,226
2025-12-11 BAKER BROS. ADVISORS LP Director Purchase · $0.01 Prefunded Warrants +190,523 $17.49 $3.3M 2,335,469
2025-12-11 BAKER BROS. ADVISORS LP Director Purchase · $0.01 Prefunded Warrants +2,095,191 $17.49 $36.6M 25,996,310
2025-06-03 BAKER BROS. ADVISORS LP Director Grant or award +10,565 336,867
2025-06-03 BAKER BROS. ADVISORS LP Director Grant or award +10,565 3,415,958
2025-06-03 BAKER BROS. ADVISORS LP Director Grant or award · Non-Qualified Stock Option (right to buy)uy) +31,695 31,695
2025-06-03 BAKER BROS. ADVISORS LP Director Grant or award · Non- Qualified Stock Option (right to buy) +31,695 31,695

Page 1 of 1 · 10 trades